Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.
Biomarker and diagnostic research for B-cell prolymphocytic leukemia has been reported in the published literature.
4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 1 PHASE2, 3 PHASE1. Research is primarily sponsored by academic and government institutions.
11 publications have been identified in PubMed for B-cell prolymphocytic leukemia. Research spans Case Report / Case Series (55%), Clinical Trial Publication (18%), and Diagnostic / Biomarker (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 |
Data assembled from 4 of 12 sources · Last updated Oct 8, 2026, 6:06 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about B-cell prolymphocytic leukemia
55%
Clinical study results | 2 | 18% |
Testing and diagnosis research | 1 | 9% |
Research summaries | 1 | 9% |
Laboratory research | 1 | 9% |
Patel VM (2026). [PMID: 41716292](https://pubmed.ncbi.nlm.nih.gov/41716292/). *EJHaem*. [Case Report / Case Series]
Maffei R (2026). [PMID: 42044618](https://pubmed.ncbi.nlm.nih.gov/42044618/). *Cancer Genet*. [Case Report / Case Series]
Ermann DA (2026). [PMID: 42078476](https://pubmed.ncbi.nlm.nih.gov/42078476/). *EJHaem*. [Clinical Trial Publication]
Maisuradze G (2025). [PMID: 39897243](https://pubmed.ncbi.nlm.nih.gov/39897243/). *Cureus*. [Case Report / Case Series]
Rocha-Rodrigues B (2025). [PMID: 40220033](https://pubmed.ncbi.nlm.nih.gov/40220033/). *Journal of hematopathology*. [Case Report / Case Series]
Groiss C (2025). [PMID: 40283646](https://pubmed.ncbi.nlm.nih.gov/40283646/). *Journal of clinical medicine*. [Clinical Trial Publication]
Giorgi S (2025). [PMID: 40937309](https://pubmed.ncbi.nlm.nih.gov/40937309/). *Mediterranean journal of hematology and infectious diseases*. [Case Report / Case Series]
Hesselager C (2025). [PMID: 40453149](https://pubmed.ncbi.nlm.nih.gov/40453149/). *Blood neoplasia*. [Basic Science / Preclinical]
Charalampopoulou S (2024). [PMID: 39471431](https://pubmed.ncbi.nlm.nih.gov/39471431/). *Blood advances*. [Diagnostic / Biomarker]
Gonzalez-Mancera MS (2024). [PMID: 38796826](https://pubmed.ncbi.nlm.nih.gov/38796826/). *International journal of hematology*. [Case Report / Case Series]